在HR+/HER2-高级乳腺癌的第一线息环境中使用CDK4/6抑制剂的现实世界经验
Ram Patel1, John Mathews2, Caroline Hamm2
1Schulich School of Medicine and Dentistry, Western University, London, ON N6A 3K7, Canada.
Current oncology (Toronto, Ont.)
|January 24, 2025
概括
在这项现实研究中,palbociclib和ribociclib在转移性乳腺癌中显示出相似的无进展生存率 (PFS) 和总生存率 (OS). 虽然ribociclib在数量上表现优于palbociclib,但差异在统计学上并不显著.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 激素受体阳性 (HR+),HER2阴性 (HER2-) 转移性乳腺癌的标准一线治疗包括CDK4/6抑制剂与芳酶抑制剂 (AI) 结合使用.
- 里程碑式的试验显示,在CDK4/6抑制剂中,可比的无进展生存期 (PFS),但整体生存期 (OS) 结果各不相同.
研究的目的:
- 在HR+/HER2-晚期乳腺癌患者中与AI一起使用palbociclib对比ribociclib的现实世界PFS和OS.
- 为了评估不同患者群体的治疗结果.
主要方法:
- 在2015年1月至2022年12月期间接受治疗的75名HR+/HER2-转移性乳腺癌成年患者的回顾性图表审查.
- 卡普兰-梅尔分析用于PFS和OS估计,使用日志级测试和Cox比例危险模型进行统计比较.
主要成果:
- 帕尔博西克利布 (74.7%) 比里博西克利布 (25.3%) 更常见. 利博西克利布患者年轻,更有可能处于更年期前.
- 对palbociclib的PFS中位数是20.3个月;中位数的OS是37.2个月.
- 里博西克利布在数值上显示了更长的PFS和OS中位数 (未达到),但在对共变量进行调整后,Cox模型在PFS (HR=0.92,p=0.86) 或OS (HR=0.95,p=0.92) 中没有发现两种药物之间的统计学上显著差异.
结论:
- 帕尔博西克利布的现实世界PFS与临床试验一致,但观察到的OS较短.
- 与palbociclib相比,ribociclib在数量上表现出优越的PFS和OS,尽管在统计学上并不显著.
- 这两种CDK4/6抑制剂的断药率相似.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.5K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
相关概念视频
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K